| At present,depression is the fourth largest disease in the world in the 21 st century.A total of 340 million people in the world suffer from the disease.The incidence rate is as high as 11%,which seriously threatens human health and causes a serious economic burden on society.Depression is mainly characterized by depressed mood,slow thinking,depressed mood,decreased cognitive activity and severe physical symptoms.Depression not only seriously affects the patient's living condition and quality of life,but also causes a huge economic burden on the patient's family.Although the study of the pathogenesis,diagnosis and treatment of depression has continued uninterrupted in recent years,the research status is not optimistic.The understanding of the pathological mechanism of depression is not thorough enough,and the diagnosis methods and methods have yet to change from subjective to objective confirmation..The treatment effect of depression is also very unsatisfactory,with low efficiency and high recurrence rate.Therefore,it is of great significance to study the pathogenesis of depression and elucidate the mechanism of drug action for the diagnosis and treatment of depression.The "Yangxinshi" tablet is a Chinese herbal compound preparation consisting of 13 Chinese medicinal herbs,Epimedium,Codonopsis pilosula,Radix Astragali,Salvia miltiorrhiza,Radix Recuti,Radix Puerariae,Hawthorn,Angelica,Corydalis,Coptis,Ganoderma lucidum,Radix Glycyrrhizae,and Ginseng..Clinically,Yangxin's tablets are mainly used for the treatment of coronary heart disease,angina pectoris,myocardial infarction,heart failure,and combined with hyperlipidemia,hyperglycemia and other diseases.According to the "double-heart theory" of the motherland medicine and the causality before and after the development of vascular depression,we found that Yangxin tablets can not only be used for the treatment of cardiovascular diseases,but also should be able to treat depression secondary to cardiovascular and cerebrovascular diseases.disease.In this study,animal models of vascular depressive mice were established and validated by using global cerebral ischemia(GCI)method with bilateral common carotid artery ligation.The efficacy evaluation of Yangxinshi in the treatment of vascular depression was evaluated.Comparison of cardiac,sham,model,and fluoxetine groups,two behavioral evaluations from the open field test and tail suspension test of mice,and correlation factors NA,DA,5-HT,and TNF-? in serum Changes in the levels of IL-1? and IL-6 can be attributed to the antidepressant effects of Yangxin's tablets similar to the positive drug fluoxetine.In order to further study the pharmacological mechanism of Yangxinshi in the treatment of vascular depression,this study used a liquid-mass spectrometry mass spectrometry analysis platform for ITRAQ-labeled proteomic analysis and metabonomics analysis,and a total of 400 differential proteins were screened.38 differential metabolites.We performed the GO and KEGG-PATHWAY proteomic analysis using the software DAVID 6.8 and verified the proteomics by q PCR.Based on the screened proteins and their differential metabolites downstream,we looked at a large number of literature and conducted proteomics-metabolomics integration analysis.Through the research on the association between different levels of biomolecules,we found that Yangxinshi treats depression.The disease affects Ca2+ signaling pathways,transport and release of excitatory neurotransmitters,nerve plasticity regulation,amino acid and energy metabolism,and improves neuronal nutrition and function. |
PDF Full Text Request